AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Alzamend Neuro (ALZN) Price Target Lowered to $45.00; Buy Rating Maintained
ByAinvest
Thursday, Aug 21, 2025 4:10 pm ET1min read
Ascendiant Capital's Edward Woo maintains a "Buy" rating for Alzamend Neuro (ALZN) but lowers the price target from $180 to $45, a 75% reduction. This adjustment reflects a more conservative outlook while still retaining confidence in the stock's potential. Alzamend Neuro is an early clinical-stage biopharmaceutical company focused on developing novel products for neurodegenerative diseases and psychiatric disorders.
Top Wall Street analysts have recently updated their price targets and ratings for a variety of stocks, with some significant changes impacting the biopharmaceutical sector. Ascendiant Capital, in particular, has made a notable adjustment to its price target for Alzamend Neuro, Inc. (ALZN), a company focused on developing novel products for neurodegenerative diseases and psychiatric disorders.Ascendiant Capital analyst Edward Woo has maintained a "Buy" rating for ALZN but has lowered the price target from $180 to $45, a 75% reduction. This adjustment reflects a more conservative outlook while still retaining confidence in the stock's potential. The change in price target comes amidst broader market volatility and uncertainty, suggesting that analysts are being cautious in their assessments.
Alzamend Neuro shares closed at $2.26 on Wednesday, July 2, 2025, according to the latest available data. The company's early clinical-stage biopharmaceutical pipeline includes innovative treatments for neurodegenerative diseases and psychiatric disorders, which hold significant promise for the future of healthcare.
Other notable changes in analyst ratings and price targets include Needham raising the price target for I-Mab (NASDAQ:IMAB) from $5 to $6, and Piper Sandler cutting the price target for Civitas Resources, Inc. (NYSE:CIVI) from $54 to $52. These adjustments underscore the dynamic nature of the market and the importance of staying informed about the latest analyst views.
For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page [1].
References:
[1] https://www.inkl.com/news/hewlett-packard-enterprise-to-rally-around-33-here-are-10-top-analyst-forecasts-for-thursday
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet